Investor Presentation Q1-Q3 2020

61 Investor presentation First nine months of 2020 Haemophilia is a rare disease with severe unmet medical needs and the market is highly competitive Number of people (000) Low diagnosis and treatment rates within haemophilia 500 400 300 200 100 0 People with haemophilia Diagnosed Haemophilia A Haemophilia B Sales of recombinant haemophilia products DKK billion 40 30 30 20 20 10 Novo NordiskⓇ 0 Inhibitor 2015 2019 2015 2019 2015 Haemophilia with inhibitors NovoSevenⓇ Coagil VII Obizur¹ Haemophilia A NovoEight® 2019 Haemophilia B RefixiaⓇ/RebinynⓇ Advate/Adynovate Idelvion Kogenate/Kovaltry/Jivi Rixubis Feiba² Hemlibra³ Xyntha/Refacto Alprolix Eloctate/Elocta Benefix Helixate/Afstyla Hemlibra Note: The inhibitor segment includes acquired haemophilia patients, patients with low titre inhibitors or with transient inhibitors, and patients on immune tolerance induction. Source: World Federation of Haemophilia (WFH) - Annual survey 2018; WFH: Closing the gap - achieving optimal care, Haemophilia 2012. 1 Obizur only indicated for acquired haemophilia; 2 Plasma-derived; 3 Part of the Hemlibra sales is used for treatment of haemophilia A patients in 2019 Source: Company reported sales and Evaluate

View entire presentation